Star Lake Bioscience Co., Inc. Class A

Star Lake Bioscience Co., Inc. Class A

SSSE:600866
4.32
CNY
+0.06
(+1.41%)
0.01EPS
353.95P/E
6.96BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A carries a market capitalization of 6.96B, placing it among publicly traded companies globally. Its enterprise value stands at 13.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.96B
Enterprise Value13.16B

Important Dates

Star Lake Bioscience Co., Inc. Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A has 1.66B shares outstanding.

Shares Outstanding1.66B

Valuation Ratios

As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A trades at a trailing price-to-earnings ratio of 353.95. The price-to-sales ratio is 0.43, and the price-to-book ratio stands at 0.91.

PE Ratio353.95
PS Ratio0.43
PB Ratio0.91
P/TBV Ratio1.00

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 0.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.16B versus a market cap of 6.96B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.82

Financial Position

As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A maintains a current ratio of 0.77, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 98.88, indicating elevated leverage, while an interest coverage ratio of -0.14 demonstrates limited ability to service its debt obligations.

Current Ratio0.77
Quick Ratio0.22
Debt / Equity98.88
Debt / EBITDA-639.37
Interest Coverage-0.14

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A posted a return on equity (ROE) of 0.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.04, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.11, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.39, useful for judging operating efficiency across full business cycles. The company generates approximately 1.53M in revenue per employee across its workforce of 10,528.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.35 indicates how many times Star Lake Bioscience Co., Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)0.25
Return on Assets (ROA)0.11
Return on Invested Capital (ROIC)-0.04
Return on Capital Employed (ROCE)0.39
Revenue Per Employee1.53M
Employee Count10,528.00
Inventory Turnover6.35

Taxes

CNY

Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A recorded 22.70M in income tax expense. That works out to an effective tax rate of 48.38, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 46.91M, leaving 19.67M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax22.70M
Effective Tax Rate48.38

Stock Price Statistics

CNY

As of the close on November 17, 2026, Star Lake Bioscience Co., Inc. Class A's stock has declined approximately 39.83% over the past 52 weeks. The 50-day moving average sits at 4.22, while the 200-day moving average is 5.49.

52-Week Price Change-39.83%
50-Day Moving Average4.22
200-Day Moving Average5.49

Income Statement

CNY

Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A generated 16.13B in revenue and converted that into 19.67M in net income, yielding earnings per share of 0.01. EBITDA reached -12.17M, while operating income came in at 166.46M.

Revenue16.13B
Gross Profit1.51B
Operating Income166.46M
Pretax Income46.91M
Net Income19.67M
EBITDA-12.17M
EBIT-12.17M
Earnings Per Share (EPS)0.01

Balance Sheet

CNY

As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A holds 1.82B in cash and equivalents against 7.78B in total debt, resulting in a net debt position of 5.42B. Total book value stands at 7.63B, with working capital of -1.89B providing operational flexibility.

Cash & Cash Equivalents1.82B
Total Debt7.78B
Net Debt5.42B
Equity (Book Value)7.63B
Book Value Per Share4.60
Working Capital-1.89B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-1.96B

Margins

Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A posted a gross margin of 9.35, reflecting its pricing power and cost economics. The operating margin of 1.03 and net profit margin of 0.12 provide insight into operational efficiency.

Gross Margin9.35
Operating Margin1.03
Pretax Margin0.29
Profit Margin0.12
EBITDA Margin-0.08

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A paid dividends of 0.44 per share. The dividend payout ratio of 2,535.07 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -19.63, meaning Star Lake Bioscience Co., Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.44
Payout Ratio2,535.07
Shareholder Yield-19.63

Stock Splits

Star Lake Bioscience Co., Inc. Class A's most recent stock split took place on May 21, 2004 with a 5:8 split ratio.

Last Split Date5/21/2004
Split Ratio5:8

Scores

As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A has an Altman Z-Score of 1.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.27